Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)-Reference-Cited by-同舟云学术

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

Published:2018-11 Issue:11 Volume:29 Page:2163-2174
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Marabelle A.,Andtbacka R.,Harrington K.,Melero I.,Leidner R.,de Baere T.,Robert C.,Ascierto P.A.^ORCID,Baurain J -F,Imperiale M.,Rahimian S.,Tersago D.,Klumper E.,Hendriks M.,Kumar R.,Stern M.,Öhrling K.,Massacesi C.,Tchakov I.,Tse A.,Douillard J -Y,Tabernero J.,Haanen J.,Brody J.

Funder

ESMO

Aduro, Amgen Europe, Bioncotech, Eisai, Idera, Lytix, Merck US (MSD), Nektar, Pfizer, and Roche

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/11/2163/27182631/mdy423.pdf

Reference34 articles.

1. The treatment of malignant tumors by repeated iniculations of erysipelas: with a report of 10 original case;Coley;Am J Med,1893

2. Intratumoral immunotherapy: using the tumor as the remedy;Marabelle;Ann Oncol,2017